View Past PerformanceMedicus Pharma 대차대조표 건전성재무 건전성 기준 점검 2/6Medicus Pharma 의 총 주주 지분은 $37.3K 이고 총 부채는 $5.3M, 이는 부채 대 자기자본 비율을 14128.3% 로 가져옵니다. 총자산과 총부채는 각각 $10.1M 및 $10.0M 입니다.핵심 정보14,128.29%부채/자본 비율US$5.27m부채이자보상배율n/a현금US$8.71m자본US$37.31k총부채US$10.02m총자산US$10.06m최근 재무 건전성 업데이트Medicus Pharma Ltd. Announces Non-Compliance with Nasdaq Minimum Bid Price RequirementApr 25Common Shares of Medicus Pharma to Be Delisted from the TSX Venture Exchange Effective At the Close of Business on February 21, 2025Feb 25Medicus Pharma Announces Intention to Voluntarily Delist from the TSX Venture ExchangeFeb 12모든 업데이트 보기Recent updatesMedicus Pharma Ltd. Announces Non-Compliance with Nasdaq Minimum Bid Price RequirementApr 25Medicus Pharma Ltd Presents New Teverelix Data Demonstrating Long-Acting Hormone SuppressionApr 17Medicus Pharma Ltd., Annual General Meeting, Jun 03, 2026Apr 14Medicus Pharma Ltd Submits Optimized Phase 2 Study Protocol to U.S. Fda for Teverelix in Acute Urinary RetentionApr 07Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset and Provides Guidance on Interpretation of Topline DatasetApr 01Medicus Pharma Ltd Reports KOL Validation of Skinject Phase 2 Data of 80% Overall Response RateMar 30Medicus Pharma Ltd. Announces Skinject® Phase 2 Principal InvestigatorMar 16Medicus Pharma Ltd. Provides Interpretation of Positive Phase 2 SkinJect DatasetMar 10Medicus Pharma Ltd Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance And 40% Histological Clearance (CR) At Day 57 In 200µg CohortMar 06Medicus Pharma Receives FDA" Study May Proceed" Clearance for Teverelix Phase 2B Study in Advanced Prostate Cancer Patients with High Cardiovascular RiskFeb 10Medicus Pharma Ltd. Announces Detailed Clinical Data on TeverelixJan 13Medicus Pharma Ltd. has filed a Follow-on Equity Offering in the amount of $15.349674 million.Dec 30Medicus Pharma Ltd. Completes Enrolment of 90 Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the SkinDec 16Medicus Pharma Ltd. Announces Chief Financial Officer ChangesDec 02Medicus Pharma Ltd. Explore Novel Treatment Innovations That May Revolutionize Treatments for Prostate and Skin CancersNov 25Medicus Pharma Ltd. Announces Filing of Fda Commission's National Priority Voucher Application (Cnpv) for Skinject (Sknjct-003) Evaluating Doxorubicin Microneedle Array (D-Mna) to Non-Mna) of the SkinjectNov 18Medicus Pharma Ltd. Receives Full Regulatory and Ethical Approvals in the United Kingdom to Expand Its Ongoing Phase 2 Clinical Study Evaluating Doxorubicin Microneedle ArrayNov 14Medicus Pharma Ltd. Announces Enrollment of the First Patient in United Arab Emirates Sknjct-004 Phase 2 Clinical StudyOct 23Medicus Pharma Ltd. announced that it expects to receive $8 million in fundingSep 18Medicus Pharma Ltd. Announces CFO ChangesSep 13Medicus Pharma Ltd. Provides Update on United Arab Emirates SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the SkinSep 09Medicus Pharma Ltd. Announces Director AppointmentsJul 23Medicus Pharma Ltd. Provides Update Regarding Its Phase 2 Clinical Study to Non-Invasively Treat BCC Using Novel D-MNA (SKNJCT-003)Jun 26+ 1 more updateMedicus Pharma Ltd. has completed a Composite Units Offering in the amount of $7.006 million.Jun 03Medicus Pharma Ltd. (NasdaqCM:MDCX) entered into a binding letter of intent to acquire Antev Limited for $11 million.Apr 29Medicus Pharma Ltd., Annual General Meeting, May 22, 2025Mar 21Medicus Pharma Ltd. Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the SkinMar 06Common Shares of Medicus Pharma to Be Delisted from the TSX Venture Exchange Effective At the Close of Business on February 21, 2025Feb 25Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell CarcinomaFeb 14Medicus Pharma Announces Intention to Voluntarily Delist from the TSX Venture ExchangeFeb 12Medicus Pharma Ltd. announced that it expects to receive $15 million in funding from Yorkville Advisors Global LPFeb 11New major risk - Shareholder dilution Jan 16Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) PatchDec 12Chief Financial Officer recently bought US$406k worth of stock Nov 22Medicus Pharma Ltd. Announces Management AppointmentsNov 19Medicus Pharma Ltd. has completed a Composite Units Offering in the amount of $4.00125 million.Nov 14Medicus Pharma Ltd. announced that it has received $11.0175 million in fundingJul 09Medicus Pharma Ltd. announced that it has received $5.845 million in fundingJul 05Medicus Pharma Ltd. announced that it expects to receive $5.845 million in fundingJun 27Medicus Pharma Ltd., Annual General Meeting, Jun 25, 2024May 03Medicus Pharma Ltd. announced a financing transactionApr 27Medicus Pharma Ltd. Announces the Appointment of Erica Monaco as Chief Operating OfficerMar 07재무 상태 분석단기부채: MDCX 의 단기 자산 ( $9.9M )은 단기 부채( $9.9M ).장기 부채: MDCX의 단기 자산($9.9M)이 장기 부채($86.0K)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: MDCX 총 부채보다 더 많은 현금을 보유하고 있습니다.부채 감소: 지난 5년 동안 MDCX의 부채 대비 자본 비율이 감소했는지 판단하기에 데이터가 부족합니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: MDCX 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 71.6 %의 역사적 비율로 계속 감소할 경우 MDCX 의 현금 활주로는 1년 미만입니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 17:24종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medicus Pharma Ltd.는 5명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kumaraguru RajaBrookline Capital MarketsJason KolbertD. Boral Capital LLC.Jason McCarthyMaxim Group2명의 분석가 더 보기
Common Shares of Medicus Pharma to Be Delisted from the TSX Venture Exchange Effective At the Close of Business on February 21, 2025Feb 25
Medicus Pharma Ltd Submits Optimized Phase 2 Study Protocol to U.S. Fda for Teverelix in Acute Urinary RetentionApr 07
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset and Provides Guidance on Interpretation of Topline DatasetApr 01
Medicus Pharma Ltd Reports KOL Validation of Skinject Phase 2 Data of 80% Overall Response RateMar 30
Medicus Pharma Ltd Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance And 40% Histological Clearance (CR) At Day 57 In 200µg CohortMar 06
Medicus Pharma Receives FDA" Study May Proceed" Clearance for Teverelix Phase 2B Study in Advanced Prostate Cancer Patients with High Cardiovascular RiskFeb 10
Medicus Pharma Ltd. Completes Enrolment of 90 Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the SkinDec 16
Medicus Pharma Ltd. Explore Novel Treatment Innovations That May Revolutionize Treatments for Prostate and Skin CancersNov 25
Medicus Pharma Ltd. Announces Filing of Fda Commission's National Priority Voucher Application (Cnpv) for Skinject (Sknjct-003) Evaluating Doxorubicin Microneedle Array (D-Mna) to Non-Mna) of the SkinjectNov 18
Medicus Pharma Ltd. Receives Full Regulatory and Ethical Approvals in the United Kingdom to Expand Its Ongoing Phase 2 Clinical Study Evaluating Doxorubicin Microneedle ArrayNov 14
Medicus Pharma Ltd. Announces Enrollment of the First Patient in United Arab Emirates Sknjct-004 Phase 2 Clinical StudyOct 23
Medicus Pharma Ltd. Provides Update on United Arab Emirates SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the SkinSep 09
Medicus Pharma Ltd. Provides Update Regarding Its Phase 2 Clinical Study to Non-Invasively Treat BCC Using Novel D-MNA (SKNJCT-003)Jun 26+ 1 more update
Medicus Pharma Ltd. (NasdaqCM:MDCX) entered into a binding letter of intent to acquire Antev Limited for $11 million.Apr 29
Medicus Pharma Ltd. Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the SkinMar 06
Common Shares of Medicus Pharma to Be Delisted from the TSX Venture Exchange Effective At the Close of Business on February 21, 2025Feb 25
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell CarcinomaFeb 14
Medicus Pharma Ltd. announced that it expects to receive $15 million in funding from Yorkville Advisors Global LPFeb 11
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) PatchDec 12
Medicus Pharma Ltd. has completed a Composite Units Offering in the amount of $4.00125 million.Nov 14